News
The level of resolution on the video was high-definition sharpness, and the foreboding shots taken by the camera guaranteed that it was both a sensation as well as its own catalyst for subsequent ...
Editas Medicine has decided to end the development of its gene-editing therapy for thalassaemia and sickle cell disease (SCD), narrowing its R&D focus and making sweeping cuts to its workforce.
Belgian biotech Galapagos is mixing things up again via a plan to split in two, separating its innovative medicines and cell therapy businesses, which will result in the loss of around 300 jobs or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results